The US Food and Drug Administration has issued a voluntary action indicated (VAI) classification for Strides Pharma Inc.'s formulations facility at Chest Ridge, New York, following a comprehensive inspection. According to reports from CNBC TV18, The Economic Times, PTI, Medical Dialogues, and ScanXNews, the USFDA conducted the inspection from December 17-23, 2025, covering current good manufacturing practices and including pre-approval inspection for drug device combination capabilities. The inspection specifically covered the company's recent filing in the nasal sprays domain. The Establishment Inspection Report (EIR) has now been issued, confirming that the inspection has been officially closed, marking a key regulatory milestone for the company's US operations. As reported by Strides Pharma Science Limited, the facility underwent an inspection conducted by the USFDA from December 17, 2025, to December 23, 2025, evaluating compliance with current Good Manufacturing Practices (cGMP) and including a pre-approval inspection for Drug-Device Combination capabilities.
Based on Strides Pharma Inc.'s response to the Form 483 issued at the conclusion of the inspection, the USFDA classified the inspection outcome as VAI. As reported by CNBC TV18, The Economic Times, PTI, Medical Dialogues, and ScanXNews, the VAI classification indicates that while observations were noted, they do not warrant regulatory enforcement action, and the agency is satisfied with the corrective measures proposed. Under the voluntary action indicated (VAI) classification, while objectionable conditions were found and documented during the inspection, the agency is not prepared to take or recommend regulatory action. The issuance of the EIR and confirmation of inspection closure removes a key regulatory overhang for the facility. The successful closure of the inspection, including device combinations, further strengthens the company's US business and near-term growth prospects, according to Strides Pharma. The company stated that it remains committed to maintaining high regulatory compliance standards and continues to focus on producing high-quality pharmaceutical products for global markets.
The Chestnut Ridge facility caters to the US market and manufactures liquids, gels, hormones, modified release products and controlled substances, supporting several current and future products for the US market. According to Strides Pharma, this successful closure of the inspection strengthens the company's US business operations and growth prospects in the American pharmaceutical market. The facility plays a strategic role in Strides' US business, supplying the US market and manufacturing a wide range of dosage forms, including liquids, gels, hormone-based products, modified-release formulations, and controlled substances. It also supports multiple ongoing and upcoming product launches targeted at the US pharmaceutical market. As reported by Strides Pharma Science Limited, the Chestnut Ridge facility primarily caters to the United States market and is involved in the manufacturing of multiple dosage forms, including liquids, gels, hormone-based products, modified-release formulations, and controlled substances. The facility supports both existing commercial products and upcoming launches targeted at the US pharmaceutical market.
Headquartered in Bengaluru, Strides operates as a global pharmaceutical company with listings on Indian stock exchanges and primarily operates in regulated markets. The company follows an 'in Africa for Africa' strategy while also maintaining an institutional business catering to donor-funded markets. Its manufacturing network spans multiple global locations, including Chennai, Puducherry, two facilities in Bengaluru, Milan in Italy, Nairobi in Kenya, and New York in the United States. According to Strides Pharma Science Limited, the company focuses on developing complex and difficult-to-manufacture pharmaceutical products that are marketed in more than 100 countries worldwide. This successful closure of the inspection strengthens the company's position in complex and differentiated product categories such as nasal sprays, with the facility supporting multiple ongoing and upcoming product launches. The inspection closure represents a crucial development for Strides' U.S. operations, particularly in expanding capabilities for drug-device combinations in the nasal sprays segment.
Shares of Strides Pharma Science Ltd. are trading 0.7% lower on Thursday at ₹860, as reported by CNBC TV18. The stock has shown positive momentum with a 16% gain over the last 12 months, indicating investor confidence despite the recent regulatory developments. This development is expected to support the company's near-term growth prospects in the US, particularly in specialty and complex generics, with the successful closure of the inspection strengthening Strides' position in complex and differentiated product categories such as nasal sprays. The company's focus on developing complex pharmaceutical products for global markets positions it well for continued growth in regulated markets worldwide.
